Periodontal Regeneration With Recombinant Human Platelet Derived Growth Factor (rH-PDGF-BB) and Allograft
Evaluation of Clinical and Radiographic Parameters in Bony Defects Treated With Recombinant Human Platelet-derived Growth Factor in Combination With Allograft
Universidad Autonoma de Nuevo Leon
30 participants
Jan 10, 2024
INTERVENTIONAL
Conditions
Summary
Growth factors are defined as small proteins that trigger a cellular response after binding to cell receptors; Tissue engineering is now clinically applicable in a commercially available system involving the use of recombinant human platelet-derived growth factor. The objective of this study is to evaluate clinical and radiographic parameters in bone defects treated with platelet-derived growth factor in combination with allograft. Our hypothesis: Defects treated with DFDBA and rhPDGF-BB have better clinically and radiographic results that the defects treated with DFDBA and saline solution.
Eligibility
Inclusion Criteria4
- Clinical diagnosis of periodontitis
- Infrabony defects of 2 walls, 3 walls and combined defects
- Patients ASA (American Society of Anesthesiologists) I and II
- Patients who smoke less than 10 cigarettes
Exclusion Criteria4
- Patients undergoing bisphosphonate therapy
- Furcation defects
- Patients with evidence of blood dyscrasias.
- Pregnant patient
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
This will be used as the control group
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06162832